Ustekinumab‑Aauz 45 mg or 90 mg Suppliers & Bulk Manufacturers
Available Forms: Subcutaneous injection, Intravenous infusion
Available Strengths: 45 mg or 90 mg
Reference Brands: Stelara(US & EU); Otulfi (ustekinumab-srlf) is a biosimilar of Stelara
Category: Biosimilars
Ustekinumab-aauz blocks interleukins 12 and 23, reducing inflammation and immune response. It effectively treats psoriasis, psoriatic arthritis, and Crohn's disease. Benefits include sustained symptom relief, improved skin and joint health, and enhanced quality of life through targeted therapy when administered under medical supervision.
Product Description:
Ustekinumab-aauz is regulated in the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality compliant with GMP and MDR standards. In the US, FDA approval requires comprehensive clinical trial data and safety validation. In the EU, CE marking certifies conformity with MDR. These products undergo validation, stability testing, and audits, with detailed documentation including safety profiles, clinical efficacy data, and manufacturing practices. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to safe, effective biologic therapies globally, supporting management of psoriasis, psoriatic arthritis, and Crohn’s disease for optimal patient outcomes.
Ustekinumab‑Aauz — third party manufacturing & bulk supply
Ustekinumab‑Aauz 45 mg or 90 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Indicative minimum order quantity
Ustekinumab‑Aauz is supplied as Subcutaneous injection, Intravenous infusion — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Ustekinumab‑Aauz listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Ustekinumab‑Aauz →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Related Products
Insulin‑Aspart‑Szjj
Strength:
100 units/mL
Form: SQ Injection
Reference Brands: NovoLog; Merilog is biosimilar to NovoLog.
View Details
Eculizumab‑Aeeb
Strength:
300 mg/20 mL (IV infusion),
Form: Injection for intravenous infusion
Reference Brands: Soliris, Bkemv- Biosimilar of Soliris, Epysqli- Biosimilar of Soliris
View Details
Omalizumab‑Igec
Strength:
75 mg/0.5 mL and 150 mg/mL
Form: Pre filled syringe
Reference Brands: Xolair, Omlyclo - a Biosimilar to Xolair
View Details
Tocilizumab-Bavi
Strength:
80 mg/4ml
Form: Intravenous infusion
Reference Brands: Actemra; Tofidence - biosimilar to Actemra (tocilizumab).
View DetailsQuick Response Guaranteed | Verified Suppliers
